Should You Buy This Mid Cap Healthcare Stock Now-BLLN

Acrobull UK Adviosry Services ltd.

February 23			2026
Name	Ticker	Sector/Industry		Market Cap	Risk Factor
BillionToOne Inc.	BLLN-NASDAQ	Healthcare		$3.91 Billion	Medium

BillionToOne, Inc. is a precision diagnostics company that quantifies biology to develop advanced molecular diagnostic tests. It offers a proprietary molecular counting platform designed to detect and measure individual DNA molecules at the single-molecule level, improving the accuracy and sensitivity of disease detection.

Recent Highlights

CEO Statement- Third quarter strengthened our belief that combining breakthrough technology with disciplined execution can produce a differentiated financial profile in molecular diagnostics,” said Oguzhan Atay, Co-founder and CEO of BillionToOne, Inc. He emphasized that sustained performance reflects operational rigor and strategic focus.

He noted that strong momentum across prenatal and oncology businesses underscores a deliberate commitment to scientific excellence and structured execution. As the company enters public markets, it remains dedicated to focus, innovation, and transforming molecular diagnostics.

Third Quarter 2025 Highlights

Total revenue rose to $83.5 million in the third quarter of 2025, compared with $38.4 million reported in the third quarter of 2024, representing a substantial 117% year-over-year increase driven by strong growth across core testing segments and expanded commercial execution.

Prenatal clinical testing revenue reached $74.1 million in the third quarter of 2025, marking a 102% increase compared with the same period in 2024, reflecting continued adoption, increased test volumes, and sustained momentum within the company’s core prenatal diagnostics business.

Oncology clinical testing revenue totaled $8.7 million in the third quarter of 2025, representing a 7.6-fold increase from $1.1 million in the prior-year quarter and a 76% sequential rise from $4.9 million in the second quarter.

Gross margin expanded to 70% in the third quarter of 2025, compared with 53% in the third quarter of 2024, reflecting a significant 17 percentage-point year-over-year improvement driven by operational efficiencies, scale benefits, and improved overall test mix.

The company accessioned 162,900 tests during the third quarter of 2025, compared with 107,900 tests in the same period of 2024, representing a 51% year-over-year increase supported by rising demand and continued commercial expansion.

Stock Observation- Building on total revenue of $83.5 million in the third quarter of 2025, compared with $38.4 million in the prior-year period, the company expects continued strong growth momentum driven by expanding test adoption, broader market penetration, and ongoing commercial execution initiatives.

Risk Involved- Financial performance of the company may have an impact on the company stock performance.

Considering all the factors and financials of the company Acrobull UK Adviosry Services ltd. maintains Customer Choose Buy for the stock.

Disclaimer- Though our research is fundamentally and technically based on Acrobull UK Adviosry Services ltd. only provides general advice on the stocks and it is imperative for the investors to do the risk assessment for themselves before investing as Acrobull UK Adviosry Services ltd. would not be liable for any loss or profit arising out through the investment made by the investors on our recommendations.

It is also advisable for the investors to consult with Financial Advisor, Broker or to seek any legal assistance as the research conducted by Acrobull UK Adviosry Services ltd. is factually based and recommendations are given in accordance with that, but it is imperative to understand that Acrobull UK Adviosry Services ltd. does not guarantee returns.

Acrobull Recommendation Based on Evaluation

Current Market Price	$85.42 USD
Acrobull Recommendation	Buy at $83.32 USD
Target Price	$95.23 USD
RSI Level	14 Day RSI 37
Total Shares Outstanding	41.22 million
Shares held by Insiders Shares Held By Institutional Investors Risk Factor Stop Loss	46.98% 32.38% Medium 5%